These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19712953)

  • 1. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.
    Musa AM; Noazin S; Khalil EA; Modabber F
    Trans R Soc Trop Med Hyg; 2010 Jan; 104(1):1-2. PubMed ID: 19712953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
    Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P; Tacchini-Cottier F; Kieny MP
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
    Botelho AC; Mayrink W; Oliveira RC
    Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines and vaccination strategies against human cutaneous leishmaniasis.
    Okwor I; Uzonna J
    Hum Vaccin; 2009 May; 5(5):291-301. PubMed ID: 19221514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccines for leishmaniasis.
    Khamesipour A
    Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.
    Okwor I; Uzonna JE
    Immunotherapy; 2009 Sep; 1(5):765-76. PubMed ID: 20636022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis.
    Vélez ID; Gilchrist K; Martínez S; Ramírez-Pineda JR; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Piazza FM
    Vaccine; 2009 Dec; 28(2):329-37. PubMed ID: 19879995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil.
    Mayrink W; Magalhaes PA; Michalick MS; da Costa CA; Lima Ade O; Melo MN; Toledo VP; Nascimento E; Dias M; Genaro O
    Parassitologia; 1992 Dec; 34(1-3):159-65. PubMed ID: 1339971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB
    Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.
    Kedzierski L; Curtis JM; Kedzierska K
    Parasitology; 2009 Jul; 136(8):833-40. PubMed ID: 19490731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in treatment of leishmaniasis.
    Akbari M; Oryan A; Hatam G
    Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific immunodeficiency and its relation to the spectrum of American cutaneous leishmaniasis.
    Convit J; Ulrich M
    Biol Res; 1993; 26(1-2):159-66. PubMed ID: 7545499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.